2020, Vol. 8, Issue 4, Part C

Methods: 45 rats were divided into 9 groups of 5 animals: 3 control groups (normal, negative and positive), 4 test groups and 2 satellite groups (control and test). All the animals except normal control received daily doses of gentamicin (80 mg/kg, i.p) during 8 days concomitantly with distilled water (negative and satellite controls), 0.9 % normal saline (positive control), AERBSM at 50, 100, 200 and 400 mg/kg (test groups), and AERBSM 400 mg/kg (satellite test group). Urinary biochemical parameters (pH, leucocyturia, glucosuria, proteinuria, osmolarity), hematological parameters (White and Red Blood Cells counts, Hemoglobin and Platelet counts), serum parameters (creatinine, urea, BUN, ALAT, ASAT, alkaline phosphatase, bilirubin, total cholesterol) and oxidative stress markers (MDA, SOD, CAT, GSH) were evaluated. Histological sections of the liver, kidney and lungs were prepared.

Results: Groups treated with AERBSM showed significant decrease of markers of kidney and liver pathology (urinary, haematological and serum) as compared to the negative control. AERBSM significantly (p<0.01) reduced MDA concentration and increased kidney and liver SOD, CAT and GSH activities compared with the negative control. Histological observation revealed that AERBSM corrected the kidney damage induced by gentamicin.

Conclusion: The observed nephroprotective effects of AERBSM could be related to its antioxidant properties.